Antitachycardia devices: Realities and promises

Lawrence S. Klein, William M. Miles, Douglas P. Zipes

Research output: Contribution to journalReview article

42 Scopus citations


Nonpharmacologic therapy for ventricular arrhythmias has gained growing attention with the development of the implantable cardioverter-defibrillator. In addition, the reports of adverse effects of drug therapy from several studies, including the Cardiac Arrhythmia Suppression Trial (CAST), have supported the need for these devices. The development of new implantable cardioverter-defibrillators that have the capability cf antitachycardia pacing, bradycardia pacing, cardioversion and defibrillation has enhanced their clinical utility. The currently available implantable cardioverter-defibrillators have been shown to significantly improve survival after sudden cardiac arrest in patients with life-threatening ventricular arrhythmias. Newer devices with expanded capabilities may reduce mortality even further. In this report the features of currently available antitachycardia devices and implantable cardioverter-defibrillators are reviewed and the features and current implant data on newer antitachycardia devices are discussed.

Original languageEnglish (US)
Pages (from-to)1349-1362
Number of pages14
JournalJournal of the American College of Cardiology
Issue number5
StatePublished - Nov 1 1991

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Antitachycardia devices: Realities and promises'. Together they form a unique fingerprint.

  • Cite this